Idecabtagene Vicleucel

The Institute for Clinical and Economic Review is taking public comment for its planned assessment of chimeric antigen receptor T-cell therapies for the treatment of multiple myeloma.

Bristol-Myers Squibb and bluebird bio resubmitted a biologics license application to the FDA for idecabtagene vicleucel — an investigational chimeric antigen receptor T-cell therapy — for the treatment of adults with relapsed or refractory multiple myeloma.

In this video, Nikhil C. Munshi, MD, from Dana-Farber Cancer Institute, discussed initial results from the KarMMa trial of idecabtagene vicleucel, a BCMA-targeted CAR T-cell therapy, which he presented at ASCO20 Virtual Scientific Program.

Idecabtagene vicleucel induced responses in nearly three-quarters of patients with relapsed or refractory multiple myeloma, according to initial results of the phase 2 KarMMa trial presented during the ASCO20 Virtual Scientific Program.

The FDA has issued a refusal to file letter regarding the biologics license application of the investigational chimeric antigen receptor T-cell therapy idecabtagene vicleucel, according to a joint statement from the manufacturers.

Bristol-Myers Squibb and its subsidiary, bluebird bio, have submitted a biologics license application to the FDA for idecabtagene vicleucel — an investigational chimeric antigen receptor T-cell therapy — for the treatment of adults with relapsed or refractory multiple myeloma.

In this video, Saad Usmani, MD, a myeloma specialist at Memorial Sloan Kettering Cancer Center, discusses the treatment outlook for CAR T-cell patients in multiple myeloma.

In this video, Saad Usmani, MD, a myeloma specialist at the Memorial Sloan Kettering Cancer Center, discusses early challenges with CAR T-cell therapy in multiple myeloma and how doctors and researchers have approached and overcome them in recent years.

In this video, Saad Usmani, MD, a myeloma specialist at the Sloan Kettering Memorial Cancer Center, discusses the latest advancements in CAR T-cell therapy in multiple myeloma, including the major progress the therapy has made over the last few years.